PMID- 23021105
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20121204
LR  - 20211021
IS  - 2191-1991 (Electronic)
IS  - 2191-1991 (Linking)
VI  - 2
IP  - 1
DP  - 2012 Sep 28
TI  - Biologic TNF inhibiting agents for treatment of inflammatory rheumatic diseases: 
      dosing patterns and related costs in Switzerland from a payers perspective.
PG  - 20
LID - 10.1186/2191-1991-2-20 [doi]
AB  - BACKGROUND: To obtain detailed real-life data on costs and dosing patterns in the 
      utilisation of the TNF inhibitors adalimumab, etanercept, and infliximab in 
      patients treated in Switzerland. METHODS: Administrative claims processed by a 
      major Swiss health insurer between 2005 and 2008 were analysed. Patients with 
      inflammatory rheumatic diseases (IRDs) with at least one prescription for 
      adalimumab, etanercept, or infliximab were identified. All-cause and 
      disease-specific costs, as well as daily costs of treatment, were calculated. 
      Dosing patterns and discontinuation rates were analysed. RESULTS: A total of 555 
      IRD patients were identified. All-cause costs during the 12 months after the 
      index event were 20,555CHF in the etanercept group, 24,152CHF in the adalimumab 
      group, and 27,614CHF in the infliximab group. The most important cost driver was 
      mean TNF inhibitor drug cost, which was 15,613CHF in the etanercept group, 
      19,166CHF in the adalimumab group, and 21,313CHF in the infliximab group. 
      Discontinuation rates during the first year after the index event were 46.8% in 
      etanercept, 41.3% in adalimumab, and 51.2% in the infliximab group. Rates of 
      dosage increase were 13.3% in the etanercept group, 13.0% in the adalimumab 
      group, and 14.1% in the infliximab group. When time on treatment was considered, 
      daily costs of treatment were similar for etanercept and adalimumab, but were 
      higher for infliximab. CONCLUSIONS: Marked differences in costs between 
      subcutaneous and intravenous therapies were observed. Among the three groups of 
      patients defined by TNF inhibitor treatment, costs for the infliximab group were 
      highest during the year after the index event.
FAU - Zeidler, Jan
AU  - Zeidler J
AD  - Center for Health Economics Research Hannover (CHERH), Leibniz University 
      Hannover, Konigsworther Platz 1, D-30167, Hannover, Germany. 
      jz@ivbl.uni-hannover.de.
FAU - Mittendorf, Thomas
AU  - Mittendorf T
FAU - Muller, Rudiger
AU  - Muller R
FAU - von Kempis, Johannes
AU  - von Kempis J
LA  - eng
PT  - Journal Article
DEP - 20120928
PL  - Germany
TA  - Health Econ Rev
JT  - Health economics review
JID - 101583209
PMC - PMC3511873
EDAT- 2012/10/02 06:00
MHDA- 2012/10/02 06:01
PMCR- 2012/09/28
CRDT- 2012/10/02 06:00
PHST- 2012/08/10 00:00 [received]
PHST- 2012/09/18 00:00 [accepted]
PHST- 2012/10/02 06:00 [entrez]
PHST- 2012/10/02 06:00 [pubmed]
PHST- 2012/10/02 06:01 [medline]
PHST- 2012/09/28 00:00 [pmc-release]
AID - 2191-1991-2-20 [pii]
AID - 10.1186/2191-1991-2-20 [doi]
PST - epublish
SO  - Health Econ Rev. 2012 Sep 28;2(1):20. doi: 10.1186/2191-1991-2-20.